These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 25397536)

  • 21. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis.
    Brinson C; Lalezari J; Gulam LH; Thompson M; Echevarria J; Treviño-Pérez S; Stock D; Samit JR; George HJ; Lataillade M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19529. PubMed ID: 25394038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Rivero A; Pérez-Molina JA; Blasco AJ; Arribas JR; Crespo M; Domingo P; Estrada V; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Moreno S; Palacios R; Pineda JA; Pulido F; Rubio R; de la Torre J; Tuset M; Gatell JM
    Enferm Infecc Microbiol Clin; 2017 Feb; 35(2):88-99. PubMed ID: 27459919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
    Elzi L; Erb S; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M;
    Arch Intern Med; 2012 Sep; 172(17):1313-21. PubMed ID: 22892835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
    Simpson KN; Baran RW; Kirbach SE; Dietz B
    Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.
    Carbone A; Galli L; Bigoloni A; Bossolasco S; Guffanti M; Maillard M; Carini E; Salpietro S; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19811. PubMed ID: 25397555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
    Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study.
    Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
    medRxiv; 2023 Jul; ():. PubMed ID: 37461582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
    Fabbiani M; Di Giambenedetto S; Quiros-Roldan E; Latini A; Vullo V; Antinori A; Castagna A; Orofino G; Francisci D; Grilli E; Madeddu G; Grima P; Rusconi S; Del Pin B; Mondi A; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19808. PubMed ID: 25397552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.
    Borghetti A; Mondi A; Piccoli B; Gagliardini R; Lamonica S; Ciccarelli N; D'Avino A; Pallavicini F; Cauda R; De Luca A; Fabbiani M; Di Giambenedetto S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19817. PubMed ID: 25397561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression.
    Llibre JM; Cozzi-Lepri A; La Rosa JA; Pedersen C; Ristola M; Losso M; Mocroft A; Mitsura VM; Ormaasen V; Maltez F; Beniowski M; Paredes R;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19810. PubMed ID: 25397554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
    Gomo ZA; Hakim JG; Walker SA; Tinago W; Mandozana G; Kityo C; Munderi P; Katabira E; Reid A; Gibb DM; Gilks CF;
    AIDS Res Ther; 2014; 11(1):32. PubMed ID: 25320632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and laboratorial impact of antiretroviral therapy in a cohort of Portuguese patients chronically infected with HIV-2.
    Miranda A; Peres S; Moneti V; Azevedo T; Aldir I; Mansinho K
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19829. PubMed ID: 25397573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.
    Huang X; Xu Y; Yang Q; Chen J; Zhang T; Li Z; Guo C; Chen H; Wu H; Li N
    Sci Rep; 2015 Feb; 5():8528. PubMed ID: 25704206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
    Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
    HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China.
    Huang X; Xu L; Sun L; Gao G; Cai W; Liu Y; Ding H; Wei H; Ma P; Wang M; Liu S; Chen Y; Chen X; Zhao Q; Yu J; Song Y; Chen H; Wu H; Qin S; Li L
    Front Pharmacol; 2019; 10():1455. PubMed ID: 31920648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.